Revolution Medicines counsel sells 765 shares

The SVP & General Counsel's sale was made under a Rule 10b5-1 trading plan adopted May 22, 2026.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) SVP & General Counsel Jeff Cislini sold 765 shares of common stock on September 25, 2026, at $207.3201 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted May 22, 2026. After the transaction, he reported direct holdings of 51,776 shares, including 37,088 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 765 shares

Net Sell 1 txn

Insider Cislini Jeff

Role SVP & General Counsel

Sold 765 shs ($159K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	765	$207.3201	$159K

Holdings After Transaction: Common Stock — 51,776 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
2. F2. Includes 37,088 restricted stock units.

Key Figures

Shares sold: 765 shares Sale price: $207.3201 per share Direct holdings after transaction: 51,776 shares +1 more

4 metrics

Shares sold 765 shares Common stock sale on September 25, 2026

Sale price $207.3201 per share September 25, 2026 transaction

Direct holdings after transaction 51,776 shares After the September 25, 2026 sale

Restricted stock units 37,088 restricted stock units Included in direct holdings after the sale

Key Terms

10b5-1 trading plan, restricted stock units

2 terms

10b5-1 trading plan regulatory

"made pursuant to a 10b5-1 trading plan adopted"

A 10b5-1 trading plan is a pre-arranged strategy that allows company insiders to buy or sell company stock at set times, regardless of their current knowledge about the company's situation. It acts like a scheduled appointment for trading, helping prevent the appearance of impropriety or insider trading. This plan provides a way for insiders to sell or buy shares in a controlled, transparent manner, offering reassurance to investors about fair trading practices.

restricted stock units financial

"Includes 37,088 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did RVMD's SVP & General Counsel sell, and at what price?

Jeff Cislini, Revolution Medicines' SVP & General Counsel, sold 765 shares on September 25, 2026, at $207.3201 per share. The transaction was made pursuant to a Rule 10b5-1 trading plan adopted May 22, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 06:00 PM Accepted by SEC EDGAR 09/29/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/25/2026		S(1)		765	D	$207.3201	51,776(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.

2. Includes 37,088 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	09/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)